Newsroom

Sorted by: Latest

-

Hancock Whitney Reports Third Quarter 2026 EPS of $1.36

GULFPORT, Miss.--(BUSINESS WIRE)--Hancock Whitney reports third quarter 2026 EPS of $1.36...
-

Alkermes to Report Third Quarter Financial Results on November 3, 2026

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Tuesday, November 3, 2026 to discuss the company’s third quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes’ website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webca...
-

DOORDASH, INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates DoorDash, Inc.’s Directors and Officers for Breach of Fiduciary Duties – DASH

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of DoorDash, Inc. (NASDAQ: DASH) failed to manage DoorDash in an acceptable manner, breaching their fiduciary duties to DoorDash, and whether DoorDash and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know: On September 22, 2026, DoorDash agreed to a $131.5 million se...
-

2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published their consensus report on the Management of Type 2 Diabetes, 2026...
-

Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that it will report third quarter 2026 financial results before the market opens on Wednesday, November 4, 2026. Management will host a live conference call on November 4, 2026 at 8:00 a.m. ET to discuss financial results and provide a business update. A w...
-

Unimed任命Sune Svenningsen为首席执行官

希腊雅典--(BUSINESS WIRE)--(美国商业资讯)-- Universal Maritime Solutions(简称“Unimed”或“公司”)是一家领先的海事医疗物资、健康合规及船员福祉解决方案提供商,也是Z Capital Group, LLC (“ZCG”)旗下私募股权基金管理平台ZCG Private Equity的投资组合公司。该公司今日宣布任命Sune Svenningsen为首席执行官。 Svenningsen先生在医疗保健供应链、运营、分销及业务转型等领域拥有近30年的国际领导经验。在加入Unimed前,他任职于International SOS,曾担任多个高级职务,包括其供应部门的首席执行官以及医疗服务业务的首席运营官。在此之前,他曾在Novartis和Missionpharma担任领导职务,负责监督亚太、中东、欧洲及美洲地区的运营工作。 ZCG创始人、总裁兼首席执行官James J. Zenni表示:“Sune在构建国际组织架构、强化运营绩效以及领导复杂的全球供应链和分销网络方面拥有深厚的经验。随着Unimed在其坚实基础之上继续向全球拓展海事健康、合...
-

Unimed nomeia Sune Svenningsen como Diretor Executivo

ATENAS, Grécia--(BUSINESS WIRE)--A Universal Maritime Solutions (“Unimed” or “the Company”), fornecedora líder de soluções em suprimentos médicos marítimos, conformidade na área da saúde e bem-estar da tripulação, e empresa integrante do portfólio da ZCG Private Equity, plataforma de gestão de fundos de private equity do Z Capital Group, LLC (“ZCG”) anunciou hoje a nomeação de Sune Svenningsen como Diretor Executivo. Mr. Svenningsen traz quase 30 anos de experiência em liderança internacional,...
-

Natuzzi S.p.A. Announces Timing of Its 2026 Second Quarter Financial Information and Conference Call

SANTERAMO IN COLLE, Bari, Italy--(BUSINESS WIRE)--Natuzzi S.p.A. Announces Timing of Its 2026 Second Quarter Financial Information and Conference Call...
-

Oito em cada 10 profissionais entrevistados afirmam que a IA impulsionará a eficiência da reestruturação, mas ainda existem lacunas na execução

WILMINGTON, Delaware--(BUSINESS WIRE)--Mais de oito em cada 10 (82%) profissionais de reestruturação esperam que a IA melhore significativamente a eficiência e a tomada de decisões. Ao mesmo tempo, a prontidão operacional e o julgamento humano experiente continuarão sendo cruciais para uma execução bem-sucedida. Isso é o que revela uma nova pesquisa da CSC, líder global em soluções de administração de negócios e conformidade. A CSC entrevistou 210 profissionais globalmente, atuantes nos setores...
-

Ocho de cada diez profesionales encuestados opinan que la IA mejorará la eficiencia de las reestructuraciones, pero que sigue habiendo dificultades en la ejecución

WILMINGTON, Delaware--(BUSINESS WIRE)--Más de ocho de cada diez (82%) profesionales de la reestructuración esperan que la IA mejore significativamente la eficiencia y la toma de decisiones. Al mismo tiempo, la preparación operativa y el criterio humano basado en la experiencia seguirán siendo fundamentales para una que una ejecución resulte exitosa. Así lo indica una nueva investigación de CSC, el proveedor líder de soluciones globales de administración empresarial y cumplimiento normativo. CSC...